Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02287285 · ClinicalTrials.gov registry record · Early Phase 1
Determinants of Diabetes Remission After Gastric Bypass Surgery
A Early Phase 1 study of Type 2 Diabetes Mellitus, sponsored by Blandine Laferrere.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT02287285 is a Early Phase 1 study of Type 2 Diabetes Mellitus that has completed, run by Blandine Laferrere. The registered enrollment target is 25 participants, below the 2,748-participant average among 122 other Type 2 Diabetes Mellitus trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02287285, a Early Phase 1 study of Type 2 Diabetes Mellitus, has completed, sponsored by Blandine Laferrere.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
Longitudinal study of beta cell function up to 2 years after GBP surgery. Evaluation of the role of endogenous glucagon-like peptide-1 (GLP-1).
Conditions Studied
Interventions
- DRUG Exendin9
Study Locations (1)
New York
- New York Obesity Research Center, Columbia University - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2014-10 |
| Est. Completion | 2019-07 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02287285
The ClinicalTrials.gov registry entry for NCT02287285 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,748-participant average among 122 other Type 2 Diabetes Mellitus trials with a reported enrollment target (99% lower). The listed sponsor is Blandine Laferrere, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Type 2 Diabetes Mellitus appearing as the primary indexed condition, and to 1 intervention - of which Exendin9 is the first listed.
NCT02287285 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT02287285 about?
NCT02287285 is a clinical study titled "Determinants of Diabetes Remission After Gastric Bypass Surgery". Longitudinal study of beta cell function up to 2 years after GBP surgery. Evaluation of the role of endogenous glucagon-like peptide-1 (GLP-1).
What is the current status of trial NCT02287285?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 25 participants. The study started on 2014-10. Estimated completion is 2019-07.
What conditions does trial NCT02287285 study?
This clinical trial studies the following conditions: Type 2 Diabetes Mellitus.
What interventions are being tested in trial NCT02287285?
The interventions under investigation include: Exendin9 (DRUG).
Who is sponsoring clinical trial NCT02287285?
This trial is sponsored by Blandine Laferrere, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02287285 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
GLP-1 and Hypoglycemia
ACTIVE NOT RECRUITING · Early Phase 1
-
The Contribution of Incretin Hormones to Post-prandial Glucose Metabolism After Roux-en-Y Gastric Bypass
COMPLETED · Early Phase 1
-
The PRECISION II Study: Evaluating the Accuracy of the LabPatch Glucose Sensing System
RECRUITING
-
A Study to Evaluate the Effect of Maridebart Cafraglutide on Insulin Sensitivity and β-cell Function in Participants With Type 2 Diabetes Mellitus
RECRUITING · Phase 1
-
An Observational Study Called FINEROD to Learn More About the Use of the Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions
RECRUITING
-
Preventing Type 2 Diabetes in Black Emergent Adult
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.